News about the Enterprise

HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission - April 14, 2014

In January 2013, the Enterprise held a consultation in Uganda on conducting efficacy trials of HIV prevention approaches in infants born to HIV-positive mothers in resource-limited settings (see the full report at

CIHR-Bill & Melinda Gates Foundation launch team grant funding opportunity on Mucosal Immunology for HIV Vaccine Development - April 9, 2014

In the field of HIV vaccines, the prevention of HIV through mucosal infection has emerged as a critical area for investigation.  Mucosal surfaces, such as vaginal and rectal surfaces, are primary sites of HIV infection and offer potentially critical opportunities for protection.  A better understanding of early events in HIV exposure may be leveraged to develop new strategies to block infection or establish early, stringent control of HIV and prevent further spread.

Scientific Highlights of AIDS Vaccine 2013, Barcelona - February 21, 2014

AIDS Vaccine 2013 was hosted by the Global HIV Vaccine Enterprise together with the Catalan Program for HIV Vaccine Research (HIVACAT) at the Barcelona International Convention Center from 7 – 10 October.  More than 900 researchers, funders, advocates and policymakers met in Barcelona for the 13th AIDS Vaccine conference at a time of significant progress and challenges in HIV prevention research.  

Symposium on Nonhuman Primate Models for AIDS, November 2013 - February 21, 2014

Highlights from the 31st Annual Symposium on Nonhuman Primate Models for AIDS held on 3–6 November 2013, in Atlanta, Georgia ( The symposium was divided into six sessions with 54 oral presentations and 83 poster presentations. Louis Picker was the keynote speaker and Beatrice Hahn made a special presentation. Here we report on five presentations organized around two themes.

Enterprise Calls for Timely Topics Proposals -- Help Identify Topics Critical to Advancing HIV Vaccine R&D - February 12, 2014

Timely Topics in HIV Vaccines is a science strategy program of the Global HIV Vaccine Enterprise, convening experts to respond to emerging priority issues in the field. Through an open call for proposals, the Enterprise aims to identify the most important strategic topics that need to be discussed and explored in a collaborative fashion.

Enterprise Webinar on Antibody Durability - December 3, 2013

The Enterprise held a webinar to share highlights from the recent thinktank on antibody durability,


Enterprise Webinar on Strategic Directions for Therapeutic Vaccines Research - November 14, 2013

The Enterprise together with AVAC, the Bill & Melinda Gates Foundation and the Treatment Action Group (TAG) hosted a consultation in September on strategic directions for therapeutic vaccines research.  Join us on Monday, 18 November at 12:00 EST for a webinar to share highlights from the consultation. You can register for the webinar here,

Join the Enterprise and Partners for a Webinar on a New Tool to Help Optimize HIV Vaccine Research - October 29, 2013

The Enterprise held a webinar on the challenges facing researchers who want to advance their vaccine candidate from preclinical studies to a first-in-human trial. The webinar introduced a new interactive webtool designed to help researchers navigate the landscape of expertise necessary for such transition and to provide estimated timelines and costs. Click here to view the webinar.

AIDS Vaccine 2013 Webcasts and Resources - October 16, 2013

AIDS Vaccine 2013 welcomed more than 900 of the world's leading vaccine researchers, funders and policy makers to Barcelona, Spain for four days of exchange, debate and direction-setting for the field. Check out the conference webcasts, and ePosters,

Experts to Report On Advances in The Search For The Ultimate HIV Prevention Tool – A Vaccine – At AIDS Vaccine 2013 - September 25, 2013

More than 450 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world's only scientific meeting dedicated exclusively to HIV vaccine research.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account